Date:2/10/2011

3,246,067) $(153,130,276) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Basic and diluted loss per common share $ (0.10) $ (0.06) $ (0.19) $ (0.12) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Weighted average number of common shares outstanding 85,323,592 55,888,710 82,853,129 55,862,879 ------------------------------------------------------------------------- ------------------------------------------------------------------------- YM BIOSCIENCES INC. Interim Consolidated Statements of Cash Flows (Expressed in Canadian dollars, unless otherwise noted) ------------------------------------------------------------------------- Three months ended Six months ended December 31, December 31, 2010 2009 2010 2009 ------------------------------------------------------------------------- (Unaudited) (Unaudited) Cash provided by (used in): Operating activities: Loss for the period $ (8,383,337) $ (3,375,537) $ (16,000,752) $ (6,878,325) Items not involving cash: Amortiza- tion of property and equipment 19,789 17,331 39,147 33,583 Amortiza- tion of intangible assets 1,127,004 265,135 2,254,008 530,271 Unrealized loss (gain) on short- term deposits (4,152) 6,888 (11,123) 9,106 Gain on disposal of property and equipment - - (10,744) - Stock-based compensation 399,475 118,046 999,935 514,690 Change in non-cash operating working capital: Accounts receivable and prepaid expenses (407,406) 87,560 (298,695) 333,595 Accounts payable, accrued liabili- ties and deferred revenue 1,364,785 (722,825) 1,699,050 (727,675) ----------------------------------------------------------------------- (5,883,842) (3,603,402) (11,329,174) (6,184,755) Financing activities: Issuance of common shares on exercise of options 238,809 51,165 253,809 62,589 Issue of common shares on exercise of warrants 850,
'/>"/>

SOURCE YM BioSciences Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
2. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
3. YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium
4. Ardea Biosciences Prices Public Offering of Common Stock
5. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
6. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
7. Whitney M. Young, Jr. Health Services and Magellan Biosciences Partner to Provide Three-Minute LeadCare II Blood-Lead Screenings to Berlin Elementary Students
8. YM BioSciences Closes Public Offering of Common Shares
9. YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING
10. Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen
11. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting